 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C19H20O2 |
| Exact Mass | 280.146 |
| CAS # | 116064-77-8 |
| PubChem CID | 3082765 |
| Appearance | Typically exists as solid at room temperature |
| Density | 1.116g/cm3 |
| Boiling Point | 423.8ºC at 760mmHg |
| Flash Point | 180.5ºC |
| Vapour Pressure | 2.17E-07mmHg at 25°C |
| Index of Refraction | 1.57 |
| LogP | 4.185 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 1 |
| Heavy Atom Count | 21 |
| Complexity | 536 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | CC(C)C1=CC2=C(C3=C(C=C2)C(C)(C)CC=C3)C(=O)C1=O |
| InChi Key | FQRLDPKLRMEKLQ-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C19H20O2/c1-11(2)14-10-12-7-8-15-13(6-5-9-19(15,3)4)16(12)18(21)17(14)20/h5-8,10-11H,9H2,1-4H3 |
| Chemical Name | 8,8-dimethyl-2-propan-2-yl-7H-phenanthrene-3,4-dione |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In Kupffer cells, dehydromiltirone (100 μg/mL; 24 h) suppresses p38 and NF-κB signaling [1]. Dehydromiltirone suppresses the phosphorylation of P38, ERK, and JNK in the MAPK signaling system; the degradation of IκB-α in the NF-κB signaling pathway; and the expression of genes associated to osteoclasts, such as NFATc1, CTSK, c-Fos, Acp5, and MMP9. Dehydromiltirone inhibits bone resorption in vitro by lowering the expression of genes linked to osteoclastogenic processes [2]. |
| ln Vivo | For five days in a row, dehydromiltirone (50–200 mg/kg, PO) guards against CCl4-induced hepatic damage. Dehydromiltirone has the ability to decrease the rise in pro-inflammatory cytokines TNF-α, IL-1, and IL-6, suggesting that it can lessen inflammation in the liver[1]. |
| Cell Assay |
Western Blot Analysis[1] Cell Types: Kupffer cells Tested Concentrations: 100 μg/mL Incubation Duration:For 24 h Experimental Results: Dramatically diminished p38 and p-p38 levels, NF-κBp65, IκB, and c-fos protein levels. |
| Animal Protocol |
Animal/Disease Models: Rat model of acute liver injury[1] Doses: 50 mg/kg, 100 mg/kg, and 200 mg/kg Route of Administration: po; daily; for five days Experimental Results: Protected liver from CCl4-induced damage. |
| References |
[1]. Salvia miltiorrhiza compounds protect the liver from acute injury by regulation of p38 and NFκB signaling in Kupffer cells. Pharm Biol. 2014 Oct;52(10):1278-85. [2]. Dehydromiltirone inhibits osteoclast differentiation in RAW264.7 and bone marrow macrophages by modulating MAPK and NF-κB activity. Front Pharmacol. 2022 Sep 21;13:1015693. |
| Additional Infomation | Dehydromiltirone has been reported in Salvia miltiorrhiza, Salvia miltiorrhiza var. miltiorrhiza, and Salvia prionitis with data available. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |